Vaxart, Inc.

Vaxart, Inc. has entered into a Cooperation Agreement with a Stockholder Group, resolving a proxy contest ahead of the 2026 Annual Meeting. Under the agreement, the Stockholder Group withdrew its director nominations and demand to inspect company records. Vaxart will work with the group to appoint a new independent director to its Board, who will also serve on the Nominating and Corporate Governance Committee. Additionally, the company will implement new corporate governance enhancements, including a director resignation policy, stock ownership guidelines, and the formation of new Board committees.

Vaxart, Inc. entered into a modification to its Project Agreement with Advanced Technology International (ATI), funded by BARDA, for its oral pill COVID-19 vaccine candidate trial. The total funding available has been reduced to approximately $345 million, a decrease of about $116 million, due to a 50% reduction in trial participants. However, the modification also releases approximately $29 million for trial completion and exploratory analyses, enabling the company to report 12-month data from the Sentinel Cohort in the coming weeks and from the main cohort in the first half of 2027.

Vaxart, Inc. filed preliminary proxy materials and issued a letter to shareholders ahead of its Annual Meeting on July 16, 2026. The company highlighted its clinical and operational progress, strategic priorities, and commitment to long-term value creation, urging shareholders to support its six director nominees. Vaxart also addressed the nomination of three dissident director candidates, emphasizing the need for experienced leadership. The company reported approximately $61 million in cash resources for Q1 2026, providing a funded runway into Q2 2027, and provided updates on its COVID-19, Norovirus, and Influenza vaccine programs.

Vaxart, Inc. filed an S-1 registration statement detailing estimated expenses of $115,000 for the registration and sale of common stock, including $85,000 for legal fees and $20,500 for accounting fees. The filing also included new Purchase and Registration Rights Agreements with Lincoln Park, both dated April 16, 2026. Additionally, the company outlined its indemnification policy for directors and officers, noting the SEC's stance that indemnification for Securities Act liabilities is against public policy.

Vaxart, Inc. has entered into a Purchase Agreement with Lincoln Park Capital Fund, LLC, securing up to $25 million in committed equity financing. Under this agreement, Vaxart may sell common stock to Lincoln Park, and Lincoln Park may resell up to 32,914,599 shares, including 447,067 commitment shares already issued. The company's common stock was delisted from Nasdaq in November 2025 and now trades on the OTCQX. Vaxart reported $61.0 million in cash as of March 31, 2026, sufficient to fund operations into Q2 2027, and an accumulated deficit of $455.0 million.

Vaxart, Inc. reported a net income of $5.179 million for the first quarter of 2026, a substantial improvement from a $15.591 million loss in the same period last year. Total revenue for the quarter increased by 88% to $39.227 million, driven primarily by higher government contract revenue and new collaboration revenue. The company also announced an agreement in April 2026 to sell up to $25.0 million in common stock to Lincoln Park Capital, extending its cash runway into Q2 2027.

Vaxart, Inc. announced its first quarter 2026 financial results, reporting a net income of $5.2 million, a significant improvement from a net loss of $15.6 million in the prior year. Revenue increased to $39.2 million, primarily driven by government contracts and a Dynavax collaboration. The company anticipates topline data from the 400-person sentinel cohort of its Phase 2b COVID-19 trial in Q2 2026 and has a cash runway into the second quarter of 2027. Additionally, Vaxart secured a flexible capital facility for up to $25 million and appointed a new director to its Board.

Vaxart, Inc. filed Amendment No. 1 to its Annual Report on Form 10-K for the year ended December 31, 2025, primarily to include information required by Part III. This section details the company's executive officers, directors, and corporate governance practices, including board independence and committee structures. The filing also noted the aggregate market value of non-affiliate common stock was $102,712,906 as of June 30, 2025, with 240,634,372 shares outstanding as of March 6, 2026.

Vaxart, Inc. announced the appointment of James B. Breitmeyer, M.D., Ph.D., to its Board of Directors, effective April 23, 2026. Dr. Breitmeyer is a veteran biotech executive, currently serving as CEO of Altay Therapeutics, Inc. and previously as President and CEO of Oncternal Therapeutics. His extensive experience in drug development and operational strategy is expected to enhance the Board's capabilities.

Vaxart, Inc. announced the appointment of James Breitmeyer, M.D., Ph.D., to its Board of Directors. Dr. Breitmeyer brings over 35 years of biopharmaceutical experience, including leading clinical development programs that resulted in eight FDA product approvals. His expertise in drug development and navigating regulatory paths is expected to strengthen the Board as Vaxart advances its oral vaccine platform.